Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

Clinical trial NCT06707753 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06707753
Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Wet Age-related Macular Degeneration (wAMD)

Start date: 2023-09-11
Primary completion: 2025-08-31
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.